| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,483 |
9,930 |
$3.85M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
15,830 |
15,298 |
$2.03M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,531 |
3,385 |
$85K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
706 |
660 |
$71K |
| 87400 |
|
2,419 |
2,267 |
$49K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,031 |
1,870 |
$48K |
| 80053 |
Comprehensive metabolic panel |
6,860 |
6,367 |
$43K |
| 85027 |
|
11,180 |
10,230 |
$41K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,139 |
2,017 |
$15K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
271 |
256 |
$13K |
| 87430 |
|
739 |
696 |
$9K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
834 |
833 |
$8K |
| 71045 |
Radiologic examination, chest; single view |
1,185 |
1,104 |
$8K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
52 |
49 |
$7K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
341 |
328 |
$7K |
| 81001 |
|
3,599 |
3,473 |
$7K |
| 76801 |
|
52 |
48 |
$5K |
| 81003 |
|
535 |
488 |
$4K |
| 83690 |
|
1,357 |
1,271 |
$4K |
| 84702 |
|
258 |
224 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,310 |
1,015 |
$3K |
| 87081 |
|
403 |
380 |
$3K |
| 84484 |
|
1,421 |
1,048 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
27 |
25 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
112 |
111 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
15 |
14 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
200 |
196 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
35 |
33 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
935 |
857 |
$1K |
| 84703 |
|
284 |
272 |
$1K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
14 |
12 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
192 |
184 |
$932.34 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
119 |
111 |
$806.01 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
14 |
13 |
$536.36 |
| 83880 |
|
170 |
155 |
$489.04 |
| 85730 |
|
432 |
410 |
$458.70 |
| 85610 |
|
618 |
582 |
$358.15 |
| 86901 |
|
186 |
178 |
$326.36 |
| 86900 |
|
187 |
178 |
$326.28 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
299 |
179 |
$322.02 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
13 |
$293.80 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15 |
13 |
$192.66 |
| 87486 |
|
15 |
14 |
$171.62 |
| 87581 |
|
15 |
14 |
$171.62 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
15 |
14 |
$171.62 |
| J2785 |
Injection, regadenoson, 0.1 mg |
47 |
46 |
$170.28 |
| 81025 |
|
40 |
40 |
$169.15 |
| 93017 |
|
74 |
73 |
$157.39 |
| 86850 |
|
15 |
13 |
$99.28 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
13 |
12 |
$78.59 |
| 87420 |
|
13 |
13 |
$65.10 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
502 |
328 |
$56.98 |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
46 |
45 |
$44.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
16 |
14 |
$9.36 |
| A9270 |
Non-covered item or service |
2,775 |
1,410 |
$0.70 |
| J2704 |
Injection, propofol, 10 mg |
383 |
366 |
$0.33 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
40 |
40 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
70 |
65 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
17 |
13 |
$0.00 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
245 |
227 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
24 |
24 |
$0.00 |